Targeting histone deacetyalses in the treatment of B- and T-cell malignancies


HDAC inhibitors (HDACI) are now emerging as one of the most promising new classes of drugs for the treatment of select forms of non-Hodgkin’s lymphoma (NHL). They are particularly active in T-cell lymphomas, possibly hodgkin’s lymphoma and indolent B cell lymphomas. Presently, two of these agents, vorinostat and romidepsin, have been approved in the US for… (More)
DOI: 10.1007/s10637-010-9591-3

3 Figures and Tables


  • Presentations referencing similar topics